PreveCeutical Medical Inc.
PRVCF
$0.0145
-$0.0005-3.33%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -8.60% | 108.14% | |||
| Depreciation & Amortization | 5.56% | -5.26% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.76% | 89.15% | |||
| Operating Income | 7.76% | -89.15% | |||
| Income Before Tax | 6.92% | -51.49% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.92% | -51.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.92% | -51.49% | |||
| EBIT | 7.76% | -89.15% | |||
| EBITDA | 7.89% | -90.84% | |||
| EPS Basic | 0.00% | -66.67% | |||
| Normalized Basic EPS | 0.00% | -50.00% | |||
| EPS Diluted | 0.00% | -66.67% | |||
| Normalized Diluted EPS | 0.00% | -50.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.31% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
